News

bit.bio and the London Institute of Mathematical Sciences (LIMS) want to recreate every human cell type.

bit.bio receives £40m of backing for technology that it claims can reliably reprogram stem cells.

Mark Kotter Bit Bio ideaSpace, focus on a founder, celebrating 10 years of idea space.

The investors behind Bit Bio's series A fundraise.

Bit Bio raises series A funding for its programming approach to human cells.

Discovery Drive-based synthetic biology Bit Bio has closed a $41.5million Series A investment.

Paul Morril, Horizon Discovery co-founder joins as CBO and Florian Schuster, Tessa Therapeutics, as CFO.

bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy.